Pharmaceutical

IBI-343 by Innovent Biologics for Solid Tumor: Likelihood of Approval

IBI-343 is under clinical development by Innovent Biologics and currently in Phase I for Solid Tumor.

Jun 20, 2024 - 04:00
IBI-343 is under clinical development by Innovent Biologics and currently in Phase I for Solid Tumor.
Read the original article

Tags:

Previous Article

Anti-RANKL Monoclonal Antibody by Jiangsu Pacific Meinuoke Bio-Pharmarceutical f...

Next Article

IMA-203CD8 by Immatics for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: ‘It was my call’: Stanford president defends decision not to correct key paper in misconduct investigation

STAT+: ‘It was my call’: Stanford president defends dec...

Apr 11, 2023

Opinion: STAT+: One way to create resilient drug supply chains: incentivize predictive models

Opinion: STAT+: One way to create resilient drug supply...

Aug 9, 2023

EC fines Teva $502m over multiple sclerosis treatment Copaxone practices

EC fines Teva $502m over multiple sclerosis treatment C...

Nov 3, 2024